Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson's disease.

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY Journal of Neurology Pub Date : 2024-09-09 DOI:10.1007/s00415-024-12669-7

Andrea Pilotto, Nicholas J Ashton, Alessandro Lupini, Beatrice Battaglio, Cinzia Zatti, Chiara Trasciatti, Stefano Gipponi, Elisabetta Cottini, Ilaria Grossi, Alessandro Salvi, Giuseppina de Petro, Marina Pizzi, Antonio Canale, Kaj Blennow, Henrik Zetterberg, Alessandro Padovani

{"title":"Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson's disease.","authors":"Andrea Pilotto, Nicholas J Ashton, Alessandro Lupini, Beatrice Battaglio, Cinzia Zatti, Chiara Trasciatti, Stefano Gipponi, Elisabetta Cottini, Ilaria Grossi, Alessandro Salvi, Giuseppina de Petro, Marina Pizzi, Antonio Canale, Kaj Blennow, Henrik Zetterberg, Alessandro Padovani","doi":"10.1007/s00415-024-12669-7","DOIUrl":null,"url":null,"abstract":"Introduction: The prognostic role of plasma neurofilament light chain (NfL), phospho-tau, beta-amyloid, and GFAP is still debated in Parkinson's disease (PD).Methods: Plasma p-tau181, p-tau231, Aβ1-40, Aβ1-42, GFAP, and NfL were measured by SIMOA in 136 PD with 2.9 + 1.7 years of follow-up and 76 controls. Differences in plasma levels between controls and PD and their correlation with clinical severity and progression rates were evaluated using linear regression analyses.Results: Patients exhibited similar distribution of plasma biomarkers but higher P-tau181, P-tau231 and lower Aβ1-42 compared with controls. NfL and GFAP correlated with baseline motor and non-motor severity measures. At follow-up, NfL emerged as the best predictor of progression with marginal effect of GFAP and p-tau181 adjusting for age, sex, disease duration, and baseline motor severity.Conclusion: The present findings confirmed plasma NfL as best predictor of progression in PD, with a marginal role of p-tau181 and GFAP.","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00415-024-12669-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The prognostic role of plasma neurofilament light chain (NfL), phospho-tau, beta-amyloid, and GFAP is still debated in Parkinson's disease (PD).

Methods: Plasma p-tau181, p-tau231, Aβ1-40, Aβ1-42, GFAP, and NfL were measured by SIMOA in 136 PD with 2.9 + 1.7 years of follow-up and 76 controls. Differences in plasma levels between controls and PD and their correlation with clinical severity and progression rates were evaluated using linear regression analyses.

Results: Patients exhibited similar distribution of plasma biomarkers but higher P-tau181, P-tau231 and lower Aβ1-42 compared with controls. NfL and GFAP correlated with baseline motor and non-motor severity measures. At follow-up, NfL emerged as the best predictor of progression with marginal effect of GFAP and p-tau181 adjusting for age, sex, disease duration, and baseline motor severity.

Conclusion: The present findings confirmed plasma NfL as best predictor of progression in PD, with a marginal role of p-tau181 and GFAP.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

作为帕金森病预后生物标志物的血浆 NfL、GFAP、淀粉样蛋白和 p-tau 物种。

导言：在帕金森病（PD）中，血浆神经丝蛋白轻链（NfL）、phospho-tau、β-淀粉样蛋白和GFAP的预后作用仍存在争议：方法：采用 SIMOA 测量了 136 名随访 2.9 + 1.7 年的帕金森病患者和 76 名对照组患者的血浆 p-tau181、p-tau231、Aβ1-40、Aβ1-42、GFAP 和 NfL。使用线性回归分析评估了对照组和帕金森病患者血浆水平的差异及其与临床严重程度和进展率的相关性：结果：与对照组相比，患者的血浆生物标志物分布相似，但P-tau181和P-tau231较高，Aβ1-42较低。NfL和GFAP与基线运动和非运动严重程度相关。在随访过程中，NfL成为预测病情恶化的最佳指标，而GFAP和P-tau181在调整年龄、性别、病程和基线运动严重程度后效果甚微：本研究结果证实，血浆NfL是预测帕金森病进展的最佳指标，p-tau181和GFAP的作用微乎其微。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Neurology 医学-临床神经学

CiteScore

10.00

自引率

5.00%

发文量

558

审稿时长

1 months

期刊介绍： The Journal of Neurology is an international peer-reviewed journal which provides a source for publishing original communications and reviews on clinical neurology covering the whole field. In addition, Letters to the Editors serve as a forum for clinical cases and the exchange of ideas which highlight important new findings. A section on Neurological progress serves to summarise the major findings in certain fields of neurology. Commentaries on new developments in clinical neuroscience, which may be commissioned or submitted, are published as editorials. Every neurologist interested in the current diagnosis and treatment of neurological disorders needs access to the information contained in this valuable journal.